Trial Profile
Phase 2 Study of a Reduced-toxicity Myeloablative Conditionning Regimen Using Fludarabine and Full Doses of iv Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2022
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Busulfan (Primary) ; Fludarabine
- Indications Graft-versus-host disease; Haematological malignancies
- Focus Therapeutic Use
- Acronyms FB4PEDIA
- 26 Aug 2022 Results of subgroup analysis (n=48) published in the Bone Marrow Transplantation
- 24 Nov 2017 Status changed from active, no longer recruiting to completed.
- 26 Jun 2017 Planned End Date changed from 1 Apr 2017 to 1 Oct 2017.